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Abstract
Background: Human mast cells are multifunctional cells capable of a wide variety of inflammatory
responses. Baicalein (BAI), isolated from the traditional Chinese herbal medicine Huangqin
(Scutellaria baicalensis Georgi), has been shown to have anti-inflammatory effects. We examined its
effects and mechanisms on the expression of inflammatory cytokines in an IL-1β- and TNF-α-
activated human mast cell line, HMC-1.
Methods: HMC-1 cells were stimulated either with IL-1β (10 ng/ml) or TNF-α (100 U/ml) in the
presence or absence of BAI. We assessed the expression of IL-6, IL-8, and MCP-1 by ELISA and
RT-PCR, NF-κB activation by electrophoretic mobility shift assay (EMSA), and IκBα activation by
Western blot.
Results: BAI (1.8 to 30 μM) significantly inhibited production of IL-6, IL-8, and MCP-1 in a dose-
dependent manner in IL-1β-activated HMC-1. BAI (30 μM) also significantly inhibited production of
IL-6, IL-8, and MCP-1 in TNF-α-activated HMC-1. Inhibitory effects appear to involve the NF-κB
pathway. BAI inhibited NF-κB activation in IL-1β- and TNF-α-activated HMC-1. Furthermore, BAI
increased cytoplasmic IκBα proteins in IL-1β- and TNF-α-activated HMC-1.
Conclusion: Our results showed that BAI inhibited the production of inflammatory cytokines
through inhibition of NF-κB activation and IκBα phosphorylation and degradation in human mast
cells. This inhibitory effect of BAI on the expression of inflammatory cytokines suggests its
usefulness in the development of novel anti-inflammatory therapies.
Background
Human mast cells are multifunctional cells involved in
numerous immune and inflammatory reactions [1,2].
Mast cells have been implicated in acute and chronic
inflammatory responses and in many diseases character-
ized by inflammation [3]. The fact that mast cells accumu-
late at sites of inflammation, such as the nasal mucosa of
patients with allergic rhinitis [4], the lung smooth muscle
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of patients with asthma [5], the skin of patients with urti-
caria [6], and the joints of patients with arthritis [7], illus-
trates the association of mast cells in these inflammatory
diseases [8]. Our previous reviews have summarized the
important role mast cells play in allergic, asthmatic, and
inflammatory responses, conditions caused by the pro-
duction of mediators and select inflammatory cytokines
[1,2].
Interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte
chemotactic protein 1 (MCP-1) are important inflamma-
tory cytokines that are secreted from activated mast cells.
IL-6 is a multifunctional protein. In innate immunity, it
stimulates the synthesis of acute-phase proteins by hepa-
tocytes and thus contributes to the systemic effects of
inflammation [9]. In adaptive immunity, it stimulates the
growth of B cells that have differentiated into antibody
producers [10]. IL-8 is a potent neutrophil chemotactic
and activating factor. It serves as a chemical signal that
attracts neutrophils to the site of inflammation [11].
MCP-1 is a member of the CC subgroup of the chemokine
superfamily [12]. MCP-1 is known for its ability to act as
a potent chemoattractant and activator of monocytes/
macrophages [13,14]. IL-1β is secreted mainly by macro-
phages. IL-1β is produced in response to various stimu-
lants, such as bacteria, viruses, and cytokines [15]. Tumor
necrosis factor-alpha (TNF-α) is a cytokine involved in
systemic inflammation and is a member of a group of
cytokines that stimulate the acute phase reaction [16,17].
Our previous studies have shown that IL-1β and TNF-α
activated human mast cells to produce selected inflamma-
tory cytokines [18,19]
Baicalein (BAI) is a flavonoid originally isolated from the
roots of the traditional Chinese herbal medicine Huang-
qin,  Scutellaria baicalensis Georgi. It has been widely
employed for many centuries in the traditional Chinese
herbal medicine as popular antibacterial, antiviral, and
anti-inflammatory agents [20]. Historically, Scutellaria
baicalensis has been used to treat respiratory tract infec-
tion, diarrhea, jaundice, and hepatitis. Recent investiga-
tions showed it had broad anti-inflammatory activities.
BAI suppressed the LPS-induced production of NO in
RAW 264.7 mouse macrophages [21]. It has shown to
have potent neuroprotective effect on LPS-induced injury
of dopaminergic neurons [22]. Recently, BAI has been
shown to inhibit inflammation through inhibition of
COX-2 gene expression [23] and to suppress LPS induced
degradation of IκBα and activation of NF-κB [24]. How-
ever, the molecular effects of BAI on inflammatory
cytokine expression by human mast cells had not been
studied.
The purpose of this study is to investigate effects and
mechanisms of BAI on inflammatory cytokine expres-
sions from IL-1β- and TNF-α-activated human mast cells.
Our results showed that BAI inhibited the production of
inflammatory cytokines through inhibition of NF-κB acti-
vation and IκBα phosphorylation and degradation in
human mast cells. This inhibitory effect of BAI on the
expression of inflammatory cytokines suggests its useful-
ness in the development of novel anti-inflammatory ther-
apies.
Methods
Reagents and cells
The baicalein (Fig. 1) was purchased from Sigma (St.
Louis, MO). HMC-1 cell line, established from a patient
with mast cell leukemia, was graciously provided by Dr.
Joseph H. Butterfield (Mayo Clinic, Rochester, MN). IL-
1β, TNF-α, and ELISA kits of IL-6, IL-8, and MCP-1 were
purchased from R&D (Minneapolis, MN). RPMI 1640
media and HEPES were obtained from GibcoBRL (Rock-
ville, MD). 2-mercaptoethanol was purchased from Sigma
(St. Louis, MO). Fetal bovine serum was obtained from
Atlanta Biologicals (Atlanta, GA). RNA-BEE was pur-
chased from Tel-Test, Inc. (Friendswood, Texas). Gene
Amp RNA PCR Core Kit was purchased from Applied Bio-
systems (Branchburg, NJ).
Cell culture
HMC-1 cells were cultured and maintained in RPMI 1640
media with 5 × 10-5 2-mercaptoethanol, 10 mM HEPES,
gentamycin 50 μg/ml, 5 μg/ml insulin, transferrin and
sodium selenite, 2 mM L-glutamine, and 5% heat inacti-
vated fetal bovine serum in a 37°C incubator with 5%
CO2. The cell cultures were maintained in 75 cm2 flasks
(Corning) [25].
Induction of cytokine production
Two ml of HMC-1 mast cells at 1 × 106 cells/ml concentra-
tion were cultured with or without various concentrations
of BAI in the presence or absence of IL-1β (10 ng/ml) or
Structure of Baicalein Figure 1
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TNF-α (100 U/ml) for 24 hrs [18]. The cultures were car-
ried out in triplicate. At the end of incubation, superna-
tants were harvested for measuring IL-6, IL-8, and MCP-1
by ELISA, and cell viability and numbers of the culture
were analyzed. The cell viability was determined by trypan
blue dye exclusion. Trypan blue dye (0.4%) was added to
cell samples in a ratio of 1:2.5 and preparations were
viewed with a standard light microscope [18]. The ratio of
live to dead cells (cell viability) was determined. The cell
viabilities of the drug groups in this study were ranging
from 93 to 95%, while that of medium control cultures
was 93%. BAI, IL-1β, or TNF-α at the concentrations used
in this study appeared to have no toxic effect to the HMC-
1 cultures.
ELISA for cytokine production
Cytokine ELISA was performed for IL-6, IL-8, and MCP-1.
ELISA was carried out on cell-free culture supernatants
using commercially available ELISA kits, according to
manufacturer's instructions as earlier described. Results
were analyzed on an ELISA plate reader (Dynatech MR
5000 with supporting software) [18].
Analysis of cytokine gene expression by RT-PCR
HMC-1 were treated with the appropriate reagents and
allowed to incubate at 37°C with 5% CO2 for 6 hours
before being harvested for RNA. RNA was extracted from
HMC-1 (3 × 106 cells) by the addition of 1 ml of RNA-
BEE. After the addition of chloroform and shaking for 1
minute the samples were centrifuged at 12,000 × g for 15
minutes at 4°C to achieve phase separation. Isopropanol
was added to the aqueous phase, and the preparation was
frozen at -20°C overnight. The following day, the samples
were centrifuged at 12,000 × g for 30 minutes at 4°C. The
RNA pellet was washed with 1 ml 75% ethanol containing
DEPC and allowed to air dry. The pellet was resuspended
in DEPC water and quantitated by optical density read-
ings at 260 nm. Reverse Transcriptase Polymer Chain
Reaction (RT-PCR) was performed with a Gene Amp RNA
PCR Core Kit according to manufacturer's instructions.
cDNA was synthesized with murine leukemia virus reverse
transcriptase (2.5 U/μl), 10× PCR buffer (500 mM KCl,
100 mM Tris-HCl, pH 8.3), 1 mM each of the nucleotides
dATP, dCTP, dGTP and dTTP; RNase inhibitor (1 U/μl),
MgCl2 (5 mM), and oligo(dT)16 (2.5 μM) as a primer. The
samples were incubated at 42°C for 20 minutes, 99°C for
20 minutes, and 5°C for 5 minutes in a DNA thermocy-
cler (Perkin-Elmer Corp., Norwalk, CT) for reverse tran-
scription. PCR of cDNA was done with MgCl2 (1.8 mM),
each of the dNTPs (0.2 mM), AmpliTaq polymerase (1 U/
50 μl), and paired cytokine-specific primers (0.2 nM of
each primer) to a total volume of 50 μl. Cycles consisted
of 1 cycle of 95°C for 2 min, 35 cycles of 95°C for 45 sec,
60°C for 45 sec, and 72°C for 1 min 30 sec, and lastly, 1
cycle of 72°C for 10 min. Ten microliters of the sample
were electrophoresed on a 2% agarose gel and stained
with ethidium bromide for viewing. Primer sequences
used are as follows: HPRT: 5' CGA GAT GTG ATG AAG
GAG ATG G 3' and 5' GGA TTA TAC TGC CTG ACC AAG
G 3'; IL-6: 5' ATG AAC TCC TTC TCC ACA AGC GC 3' and
5' GAA GAG CCC TCA GGC TGG ACT G 3'; IL-8: 5' ATG
ACT TCC AAG CTG GCC GTG GCT 3' and 5' TCT CAG
CCC TCT TCA AAA ACT TCT C 3'; and MCP-1: 5' GTA
GAA CTG TGG TTC AAG AGG 3' and 5' AGC CAC CTT
CAT TCC CCA AG 3'. Densitometry was done by normal-
izing target genes to house keepers using Un-Scan-It Ver-
sion 5.1 software (Orem, UT).
NF-κB assay in HMC-1
HMC-1 were stimulated with PMA, IL-1β, TNF-α, and/or
BAI for 24 hours, and then harvested for electrophoretic
mobility shift assay (EMSA) [26-29]. Cells were washed
with PBS and mixed with one hundred microliters of
hypotonic buffer which contains: 10 mM HEPES pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithio-
threitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF), 1 μM aprotinin, 1 μM pepstatin, 14 μM leupep-
tin, 50 mM NaF, 30 mM β-glycerophosphate, 1 mM
Na3VO4, and 20 mM p-nitrophenyl phosphate. Cells were
incubated over ice for 30 minutes and then vortexed after
the addition of 6.25 μl of 10% of Nonidet P-40. After 2
minutes of centrifugation at 30,000 × g, supernatants were
kept at -80°C while the pellets were collected and vor-
texed every 20 minutes for 3 hours in 60 ml of a hyper-
tonic salt solution: 20 mM HEPES pH 7.9, 0.4 M NaCl, 1
mM EDTA, 1 mM EGTA, 12 mM DTT, 1 mM PMSF, 1 μM
aprotinin, 1 μM pepstatin, 14 μM leupeptin, 50 mM NaF,
30 mM β-glycerophosphate, 1 mM Na3VO4, and 20 mM
p-nitrophenyl phosphate. Nuclear translocation of NF-κB
was analyzed by the EMSA using the nuclear fraction.
Seven micrograms of nuclear protein were added to 2 ml
of binding buffer (Promega, Madison, WI), and 35 fmol
of double stranded NF-κB consensus oligonucleotide (5'
AGT TGA GGG GAC TTT CCC AGG C 3') (Promega, Mad-
ison, WI) end labeled with γ-P32 ATP (Amersham Bio-
sciences, Piscataway, NJ). The samples were incubated at
room temperature for 20 minutes and run on a 5% non-
denaturing polyacrylamide gel for 2 hours. A supershift
assay using antibodies to P65 and P50 was performed to
confirm NF-κB binding specificity as previously described
[26-29].
Western blot analysis for IκBα
Cytoplasmic proteins (40 μg) were mixed with 2× SDS
sample buffer, heated at 95°C for 5 min, and separated by
SDS-polyacrylamide (12.5%) gel electrophoresis [27,30].
The separated proteins were transferred onto Hybond
enhanced chemiluminescence membranes (Amersham)
and then incubated with an appropriate rabbit primary
antibody [IκBα antibody (Santa Cruz Biotechnology) orClinical and Molecular Allergy 2007, 5:5 http://www.clinicalmolecularallergy.com/content/5/1/5
Page 4 of 10
(page number not for citation purposes)
phosphorylated IκBα antibody (New England Biolabs)]
in Tris-buffered saline – 0.05% Tween 20 containing 5%
nonfat dry milk for 1 – 2 hours at room temperature. After
they were washed three times in Tris-buffered saline –
0.05% Tween 20, the membranes were incubated with
peroxidase-conjugated goat anti-rabbit Ig G (Sigma
Chemical) for 1 hour at room temperature. After three
washes in PBS, the conjugated peroxidase was visualized
by enhanced chemiluminescence according to the manu-
facturer's instructions (Amersham). The protein signals of
IκBα were quantified by scanning densitometry
(Genomic Solutions).
Statistical analysis of the data
All experiments were done in triplicate. The data were ana-
lyzed by Student's two-tailed t-test using Statistica soft-
ware (StatSoft, Inc., Tulsa, OK). All data were reported as
means ± SE. A p-value of less than 0.05 was considered sig-
nificant.
Results
BAI inhibits IL-1β- and TNF-α-induced IL-6, IL-8, and 
MCP-1 production in mast cells
First, the effect of BAI on production of the inflammatory
cytokines, IL-6, IL-8, and MCP-1, from IL-1β- and TNF-α-
activated HMC-1 cells was studied. BAI at concentrations
of 1.8, 3.6, 7.5, 15, and 30 μM have been proved to be
non-toxic to HMC-1 [31]. Two mL of HMC-1 at 1 × 106
cells/mL were cultured with the above mentioned concen-
trations of BAI in the presence or absence of IL-1β (10 ng/
mL) for 24 hrs. The cell free supernatants were collected
and assayed for cytokines by ELISA. The results are shown
in Fig. 2. IL-1β at 10 ng/mL concentration markedly
induced IL-6, IL-8, and MCP-1 production from HMC-1
(326.7 ± 8.0, 368.1 ± 19.1, and 432.4 ± 40.9 pg/mL,
respectively). BAI alone did not induce cytokine produc-
tion from HMC-1. However, BAI at 15 and 30 μM concen-
trations significantly decreased the IL-1 β-induced IL-6
production to 192.7 ± 18.7 and 74.6 ± 14.6 pg/mL,
respectively (p < 0.0005 and p < 0.00005, respectively)
and MCP-1 production to 112.9 ± 3.1 and 51.2 ± 0.5 pg/
mL, respectively (both p < 0.0005). BAI at all tested con-
centrations (1.8 to 30 μM) significantly decreased the IL-
1 β-induced IL-8 production, in a dose-dependent man-
ner, to 316.4 ± 1.3, 177.4 ± 13.2, 147.6 ± 5.4, 54.9 ± 3.3,
and 46.9 ± 4.4 pg/mL, respectively (p < 0.05 for 1.8 μM, p
< 0.0005 for 3.6 μM, and p < 0.00005 for all the rest).
TNF-α also activated HMC-1 to product inflammatory
cytokines, but to a lesser extent (136.2 ± 15.4 pg/mL for
IL-6, 27.0 ± 1.5 pg/mL for IL-8, and 160 ± 20.4 pg/mL for
MCP-1). Since BAI at 30 μM was the most effective con-
centration in inhibition of cytokine production in IL-1β-
activated HMC-1, we decided to only use this concentra-
tion in experiments with TNF-α-activated HMC-1. Simi-
larly, BAI at 30 μM concentration has been shown to
significantly decrease the TNF-α-induced production of
IL-6, IL-8, and MCP-1 to 3.0 ± 0.3, 0.0 ± 0.0, and 23.4 ±
0.23 pg/mL, respectively (p < 0.00005 for IL-8 and p <
0.0005 for the rest) (Fig. 3).
Effects of BAI on IL-6, IL-8, and MCP-1 gene expressions in 
activated mast cells
To study effects of BAI on inflammatory cytokine gene
expression, the experiments were performed using IL-1β-
and TNF-α-activated HMC-1. HMC-1 were treated with
IL-1β or TNF-α in the presence or absence of BAI (30 μM)
Effects of Baicalein (BAI) on production of IL-6, IL-8, and  MCP-1 from IL-1β-activated HMC-1 cells Figure 2
Effects of Baicalein (BAI) on production of IL-6, IL-8, 
and MCP-1 from IL-1β-activated HMC-1 cells. To each 
well of a 6-well culture plate, two ml of HMC-1 (1 × 106 cells/
ml) were cultured alone (Control), or in the presence of BAI 
(30 μM), IL-1β (10 ng/ml), and the combinations of IL-1β (10 
ng/ml) with different concentrations of BAI (1.8 to 30 μM) for 
24 hrs in triplicate. Supernatants were harvested for measuring 
IL-6, IL-8, and MCP-1 by ELISA. The IL-6 (Panel A), IL-8 (Panel 
B), and MCP-1 (Panel C) production was significantly 
decreased when BAI was added in IL-1β-activated HMC-1 
cells. *, +, and # indicate p < 0.05, <0.0005, and <0.00005, 
respectively, when compared with the IL-1β-treated group.
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for 6 hours and harvested for transcriptional analysis via
RT-PCR. IL-1β-treated HMC-1 increased IL-6, IL-8, and
MCP-1 mRNA transcription (Fig. 4A). The intensities of
the cytokine and house keeping gene (HPRT) bands were
measured by densitometry, and the ratio of the cytokine
to the house keeping gene was calculated and assigned as
the intensity index. In the presence of BAI, the expression
of IL-6 and MCP-1 was slightly decreased, while IL-8
faintly increased. The intensity indices for IL-6 expression
were 0.74 and 0.67 for the IL-1β and the IL-1β plus BAI
groups, respectively. The intensity indices for IL-8 expres-
sion were 0.76 and 0.79 for the IL-1β and the IL-1β plus
BAI groups, respectively, while that for MCP-1 expression
were 0.74 and 0.71 for the IL-1β and the IL-1β plus BAI
groups, respectively.
In TNF-α-activated HMC-1, BAI markedly decreased the
inflammatory cytokine gene expression (Fig. 4B). The
intensity index for IL-6, IL-8, and MCP-1 expression in
TNF-α-activated HMC-1 were 0.73, 0.74, and 0.96, respec-
tively. When HMC-1 cells were activated by TNF-α in the
presence of BAI (30 μM), the intensity index for IL-6, IL-8,
and MCP-1 were decreased to 0.51, 0.66, and 0.69, respec-
tively.
Role of NF-kB activation in the inhibitory effect of BAI on 
inflammatory cytokine production from IL-1β- and TNF-α-
activated mast cells
NF-κB is an important transcription factor that mediates
the transcription of many proinflammmatory cytokine
genes [32,33]. In order to study the role that NF-κB plays
in the inhibitory effect of BAI on inflammatory cytokine
production, NF-κB activation was analyzed in HMC-1 cul-
tured with IL-1β or TNF-α in the presence or absence of
BAI (30 μM). In the presence of BAI, NF-κB translocation,
as seen by a shift in oligonucleotide binding in EMSA gels,
was decreased in the IL-1β- (Fig. 5A) and TNF-α-activated
HMC-1 (Fig. 5B).
Role of IkBα proteins in the inhibitory effect of BAI on 
inflammatory cytokine production from IL-1β- and TNF-α-
activated mast cells
The activation of NF-κB requires phosphorylation and
proteolytic degradation of the inhibitory protein IκBα
[34]. To determine whether the inhibitory activity of BAI
is due to its effect on IκBα phosphorylation and degrada-
tion, we used Western blot analysis to examine the cyto-
plasmic levels of IκBα in HMC-1 after treatment with IL-
1β or TNF-α in the presence or absence of BAI (30 μM).
The data showed that in the presence of BAI, the IκBα pro-
tein levels were markedly increased in the IL-1β- (Fig. 6A)
and TNF-α-activated HMC-1 (Fig. 6B).
Discussion
Inflammatory cytokines are important factors in chronic
inflammation, allergy, asthma, atherogenesis, and
autoimmune diseases. Human mast cells play an integral
role in the inflammatory response by accumulating at
sites of inflammation and mediating the production of
inflammatory cytokines [35]. In spite of advances in the
pharmacological management of above mentioned dis-
eases and symptoms, to discover effective, alternative anti-
inflammatory reagents is still in need. Several Chinese
herbal medicines have anti-bacterial and viral properties
and been used for treatment of chronic inflammation.
Effects of Baicalein (BAI) on production of IL-6, IL-8, and  MCP-1 from TNF-α-activated HMC-1 cells Figure 3
Effects of Baicalein (BAI) on production of IL-6, IL-8, 
and MCP-1 from TNF-α-activated HMC-1 cells. To each 
well of a 6-well culture plate, two ml of HMC-1 (1 × 106 cells/
ml) were cultured alone (Control), or in the presence of BAI 
(30 μM), TNF-α (100 U/ml), and the combinations of TNF-α 
(100 U/ml) with BAI (30 μM) for 24 hrs in triplicate. Superna-
tants were harvested for measuring IL-6, IL-8, and MCP-1 by 
ELISA. The IL-6(Panel A), IL-8 (Panel B), and MCP-1 (Panel C) 
production was significantly decreased when BAI was added in 
TNF-α-activated HMC-1. + and # indicate p <0.0005 and 
<0.00005, respectively, when compared with the TNF-α-
treated group.
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Previously, we have screened several Chinese herbal med-
icines and found that the compound Baicalein (BAI, Fig 1)
isolated from Huangqin (Scutellaria baicalensis Georgi)
has a great inhibitory effect on the production of IL-6
from IL-1β-activated HMC-1 in a dose dependent fashion
[31]. The purpose of this study is to further investigate
inhibitory effects and mechanisms of BAI on inflamma-
tory cytokine expression from IL-1β- and TNF-α-activated
human mast cells. Ultimately it is hoped that BAI will be
a possible candidate for future development of novel anti-
inflammatory therapies.
In this study, we examined effects of BAI on the produc-
tion of important inflammatory cytokines, IL-6, IL-8, and
MCP-1, from IL-1β- or TNF-α-activated HMC-1. We
observed that BAI (1.8 to 30 μM) significantly inhibited
production of IL-6, IL-8, and MCP-1 in a dose-dependent
manner in IL-1β-activated HMC-1 (Fig. 2). Since BAI 30
μM was the most effective concentration, we only used
RT-PCR analysis of effects of BAI on the gene expression of IL-6, IL-8, and MCP-1 in IL-1β- and TNF-α-activated HMC-1 cells Figure 4
RT-PCR analysis of effects of BAI on the gene expression of IL-6, IL-8, and MCP-1 in IL-1β- and TNF-α-activated 
HMC-1 cells. HMC-1 cells were treated with: A. IL-1β (10 ng/ml) with and without BAI (30 μM), and B. TNF-α (100 U/ml) with 
and without BAI (30 μM) for 6 hours before harvested for RNA preparation. RNA was subjected to RT-PCR with specific primers 
for target genes. HPRT was used as a house keeping gene to ensure equal loading. There were mild decreased gene expressions in 
IL-6 and MCP-1 and mild increased in IL-8 by BAI co-cultured with IL-1β-activated HMC-1 (Panel A). However, markedly 
decreased gene expressions of IL-6, IL-8, and MCP-1 were showed by BAI co-cultured with TNF-α-activated HMC-1 (Panel B). By 
densitometric analysis, the ratio of the expression of cytokine to HPRT was calculated and assigned as the intensity index as 
shown in the bar graph.
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this dose to treat TNF-α-activated HMC-1 cells and found
it also significantly inhibited production of IL-6, IL-8, and
MCP-1 in TNF-α-activated HMC-1 (Fig. 3). The results
show that BAI significantly inhibit the production of
inflammatory cytokines from human mast cells. The cell
viabilities of the drug groups in this study were ranging
from 93 to 95%, while that of medium control cultures
was 93% (Data not shown). Thus, this inhibitory effect
appears not due to the toxic effect of BAI on HMC-1 cells.
Moreover, the gene expression, analyzed by RT-PCR, of
these inflammatory cytokines was mildly decreased in IL-
1β-activated HMC-1 (Fig. 4A) and markedly decreased in
TNF-α-activated HMC-1 (Fig. 4B) when BAI was pre-
sented. These suggest that inhibitory effect of BAI on
cytokine productions is through the decrease of cytokine
mRNA transcription.
BAI is a flavonoid extracted from the root of Scutellaria
baicalensis Georgi, which has been used as anti-inflam-
matory medicine in China for years. In recent studies, an
important flavonoid, quercetin, has been reported to exert
a strong inhibitory effect on the production of IL-6, MCP-
1, and histidine decarboxylase (HDC) mRNA transcrip-
tion from mast cells [36-38]. Our results confirmed that
BAI, as a flavonoid, could also strongly inhibit production
of inflammatory cytokines of IL-6, IL-8, and MCP-1 from
activated mast cells through the decrease of mRNA tran-
scription. On the other hand, in our study, the cytokine
gene expression was mildly decreased in IL-1β-activated
HMC-1 (Fig. 4A), but markedly decreased in TNF-α-acti-
vated HMC-1 (Fig. 4B) by addition of BAI. It appears that
BAI had a differential effect on the cytokine gene expres-
sion in mast cells activated by different stimulants. It has
been shown that acute phase response cytokines, IL-1β
and TNF-α, activate human mast cells by IL-1 receptor (IL-
1R) and TNF-α receptor (TNFR) signaling pathways,
respectively, involving MyD88 dependent and/or inde-
pendent protein kinases [39,40]. This differential effect of
BAI on activated mast cells warrants further studies.
The expression of various inflammatory cytokines is regu-
lated by transcription factors. The activation of the NF-κB
transcription plays an important role in inflammation
through its ability to induce the transcription of proin-
flammatory genes [41]. Previously, glucocorticoids that
have frequently been used for the treatment of inflamma-
tory diseases, allergy, and autoimmune diseases were sug-
gested to suppress NF-κB activation. Glucocorticoids are
thought to induce the transcription of IκBα, resulting in
an enlarged IκBα pool, and therefore reduced active NF-
Effects of BAI on NF-κB translocation in IL-1β- and TNF-α-activated HMC-1 cells Figure 5
Effects of BAI on NF-κB translocation in IL-1β- and TNF-α-activated HMC-1 cells. HMC-1 cells were cultured with IL-
1β or TNF-α in the presence or absence of BAI (30 μM) for 24 hours. NF-κB translocation was analyzed by a shift in oligonucle-
otide binding in EMSA gels. NF-κB translocation was decreased by BAI co-cultured with IL-1β (panel A) and TNF-α (panel B) 
when compared with the IL-1β or TNF-α alone. Densitometric analysis of NF-κB was expressed as integrated intensity and shown 
in the bar graph.
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κB in the nucleus [42]. Additionally, 12-lipoxygenase (12-
LOX) has been implicated as a mediator of inflammation,
atherosclerosis, and cancer [43-45]. Several in vitro studies
have suggested 12/15-LOX products to be co-activators of
peroxisomal proliferator activating-receptors (PPAR), reg-
ulators of cytokine generation, and modulators of gene
expression related to inflammation resolution. The damp-
ening effect of PPAR on inflammation is via their inhibi-
tory activity on expression of NF-κB [46-48]. As BAI is
known as a 12-LOX inhibitor, we speculated the mecha-
nism by which BAI inhibited inflammatory cytokines was
through the NF-κB/IκBα pathway. Therefore, we analyzed
NF-κB activation and examined the cytoplasmic levels of
IκBα in HMC-1 after treatment with IL-1β or TNF-α in the
presence or absence of BAI. Our data showed BAI
decreased NF-κB binding activity (Fig. 5) and increased
IκBα proteins in cytoplasm in IL-1β- and TNF-α-activated
mast cells (Fig. 6). The results suggest BAI inhibits the NF-
κB activation via inhibition of IκBα phosphorylation and
degradation.
Conclusion
In searching for effective drugs to treat inflammatory
related diseases, we found baicalein from the Chinese
herbal medicine possesses strong inhibitory effect on pro-
duction of selected inflammatory cytokines from human
mast cells. The inhibitory mechanism appears to be due to
inhibition of NF-κB activation pathway and IκBα phos-
phorylation and degradation. This inhibitory effect of bai-
calein on the expression of inflammatory cytokines
indicates its usefulness in the development of novel anti-
inflammatory therapies.
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